^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    1d
    A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=31, Terminated, Shanghai Junshi Bioscience Co., Ltd. | N=198 --> 31 | Recruiting --> Terminated; The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns
    Enrollment change • Trial termination
    |
    Loqtorzi (toripalimab-tpzi) • tifcemalimab (TAB004)
    1d
    AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2) (clinicaltrials.gov)
    P=N/A, N=6000, Not yet recruiting, Imperial College London
    New trial
    2d
    HASCHANGE02: Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach (clinicaltrials.gov)
    P2, N=30, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    3d
    LINC01614 promoted malignant progression of stomach adenocarcinoma via miR-129-2-3p. (PubMed, Cytotechnology)
    LINC01614 may represent a novel molecular target for STAD. The online version contains supplementary material available at 10.1007/s10616-025-00870-z.
    Journal
    |
    MIR129 (MicroRNA 129) • MIR129-2 (MicroRNA 129-2)
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    4d
    Depletion of LINC01133 from cancer-associated fibroblasts exacerbates the progression of gastric adenocarcinoma. (PubMed, iScience)
    In vivo studies confirmed that either overexpression of LINC01133 or inhibition of miR-199a-5p suppresses gastric adenocarcinoma cell growth. In summary, LINC01133 re-activation may serve as a potential therapeutic strategy for inhibiting metastasis in gastric adenocarcinoma.
    Journal
    |
    KLF4 (Kruppel-like factor 4) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • CDC42 (Cell Division Cycle 42) • MIR199A (MicroRNA 199a) • LINC01133 (Long Intergenic Non-Protein Coding RNA 1133) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)
    6d
    Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors. (PubMed, Sci Rep)
    This analysis of a phase II randomized trial included patients with gastric adenocarcinoma treated with Menadione plus XELOX or XELOX alone. PFS analysis showed a higher risk of progression in No-CTC responders, with HRs of 2.28 at 3 months and 10.5 at 15 months (p < 0.001). Patients without CTC response had worse OS and PFS in both treatment groups, suggesting that CTC response could be a valuable predictor of clinical outcomes, warranting more intensive monitoring and tailored therapies for specific subgroups.
    Clinical • Journal • Circulating tumor cells
    |
    CDC25B (Cell Division Cycle 25B) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    |
    capecitabine • oxaliplatin
    6d
    Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Jul 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    6d
    GRACIE: Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=88, Recruiting, UNICANCER | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab)
    8d
    First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [225Ac]Ac-DOTA-LM3. (PubMed, Clin Nucl Med)
    Due to rising levels of bilirubin 2 months after therapy, an endoscopic retrograde cholangiopancreatography diagnosed bile duct stenosis and gastric adenocarcinoma (cause of death). Autopsy findings did not reveal any residual NEN, indicating complete remission after one cycle of alpha-PRRT.
    Journal
    |
    SSTR (Somatostatin Receptor)
    8d
    Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy. (PubMed, Biomedicines)
    In the gastric cancer validation cohort, all tumors with PTVs demonstrated a partial response to anti-PD-1 therapy. We report CREBBP and EP300 coding mutations as novel potential surrogate biomarkers for hypermutation in gastroesophageal adenocarcinomas and demonstrate their association with favorable immunotherapy outcomes, supporting their potential clinical utility for patient stratification.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300)
    |
    TMB-H • MSI-H/dMMR
    9d
    Integrative analysis of Helicobacter pylori-driven stomach adenocarcinoma reveals epigenetic deregulation, immune evasion, and therapeutic resistance. (PubMed, Hereditas)
    This study identifies THBS2, CTNNB1, COL4A1, and E2F3 as key H. pylori-associated oncogenic drivers in STAD. Functional assays demonstrate that H. pylori enhance malignant phenotypes through COL4A1 and CTNNB1, while gene silencing reverses these effects. These findings highlight the hub genes and their regulatory miRNAs as promising diagnostic biomarkers and potential therapeutic targets in H. pylori-related gastric cancer.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • THBS2 (Thrombospondin 2) • COL4A1 (Collagen Type IV Alpha 1 Chain) • E2F3 (E2F transcription factor 3)